60 Degrees Pharmaceuticals Inc. Warrant

News & Events

Press Releases

In The Media

1. 60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

   GlobeNewswire JUL 17, 2025 8:01 AM EDT
   Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lym...
   READ ARTICLE

2. 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

   GlobeNewswire JUL 16, 2025 4:01 PM EDT
   WASHINGTON, July 16, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Compa...
   READ ARTICLE

3. 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

   GlobeNewswire JUL 15, 2025 9:10 AM EDT
   WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Compa...
   READ ARTICLE

4. 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

   GlobeNewswire JUL 15, 2025 7:01 AM EDT
   New Drug Application intended for 2026, subject to generation of positive data from three U.S. cl...
   READ ARTICLE

5. 60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

   GlobeNewswire JUL 14, 2025 4:01 PM EDT
   Data from three independent clinical studies demonstrate utility of tafenoquine to treat acut...
   READ ARTICLE

6. 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

   GlobeNewswire JUN 4, 2025 8:56 AM EDT
   New 8-count bottles now available through major retail pharmacies ARAKODA® is the only w...
   READ ARTICLE

7. Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

   GlobeNewswire JUN 3, 2025 8:49 AM EDT
   25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. C...
   READ ARTICLE

8. 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

   GlobeNewswire MAY 15, 2025 4:31 PM EDT
   Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross prof...
   READ ARTICLE

9. Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

   GlobeNewswire APR 22, 2025 8:44 AM EDT
   In a survey representative of the general U.S. adult population, 1.26 percent of respondents ...
   READ ARTICLE

10. Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

    GlobeNewswire APR 10, 2025 8:31 AM EDT
    WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development ...
    READ ARTICLE